Skip to main content
Advertisement
Advertisement

AVTX

AVTX logo

Avalo Therapeutics, Inc. Common Stock

15.41
USD
Sponsored
-1.10
-6.68%
Sep 23, 15:54 UTC -4
Open

AVTX Earnings Reports

Positive Surprise Ratio

AVTX beat 16 of 37 last estimates.

43%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.62
Implied change from Q2 26 (Revenue/ EPS)
--
/
-25.30%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-71.69%

Avalo Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, AVTX reported earnings of -0.83 USD per share (EPS) for Q2 26, missing the estimate of -0.59 USD, resulting in a -39.85% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.74% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.62 USD, with revenue projected to reach -- USD, implying an decrease of -25.30% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Avalo Therapeutics, Inc. Common Stock reported EPS of -$0.83, missing estimates by -39.85%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.74%, changed from $18.84 before the earnings release to $18.70 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 9 analysts, Avalo Therapeutics, Inc. Common Stock is expected to report EPS of -$0.62 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement